4//SEC Filing
Moxie Dwight 4
Accession 0001479290-23-000076
CIK 0001479290other
Filed
May 15, 8:00 PM ET
Accepted
May 16, 8:29 PM ET
Size
7.2 KB
Accession
0001479290-23-000076
Insider Transaction Report
Form 4
Moxie Dwight
CLO & GC
Transactions
- Award
Common Stock
2022-02-02+42,349→ 90,566 total - Sale
Common Stock
2023-05-15$34.55/sh−21,401$739,338→ 69,165 total
Footnotes (3)
- [F1]Represents settlement of a performance-based restricted stock unit ("PSU") granted on February 2, 2022. On May 12, 2023, the Issuer's Compensation Committee certified 100% of the PSUs eligible to vest based on pre-established criteria related to the price of the Issuer's common stock.
- [F2]Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PSUs. This sale is mandated by the Issuer's sell to cover agreement that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
- [F3]The price reported in Table 1, Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.02 to $34.55. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Documents
Issuer
Revance Therapeutics, Inc.
CIK 0001479290
Entity typeother
Related Parties
1- filerCIK 0001803375
Filing Metadata
- Form type
- 4
- Filed
- May 15, 8:00 PM ET
- Accepted
- May 16, 8:29 PM ET
- Size
- 7.2 KB